Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
The Journal of Biological Chemistry|January 6, 2005
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivoAlan G Olivero, Charles Eigenbrot, Richard Goldsmith, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2012
Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Nicole Blaquiere, Vickie Tsui, et al.
ACS Medicinal Chemistry Letters|April 21, 2016
Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTORTimothy P Heffron, Chudi O Ndubaku, Laurent Salphati, et al.
Rheumatology (Oxford, England)|October 8, 2013
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)Maria J Cuadrado, Maria L Bertolaccini, Paul T Seed, et al.
Journal of Medicinal Chemistry|September 6, 2012
The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase αTimothy P Heffron, Laurent Salphati, Bruno Alicke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 18, 2016
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human GlioblastomaLaurent Salphati, Bruno Alicke, Timothy P Heffron, et al.
Lupus|August 12, 2016
Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre studyO Amengual, R Forastiero, M Sugiura-Ogasawara, et al.
Molecular Cancer Therapeutics|October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathwayJeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters|June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinaseSteven T Staben, Michael Siu, Richard Goldsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2012
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrierLaurent Salphati, Timothy P Heffron, Bruno Alicke, et al.
Pageof 12